Prolonged response to pemigatinib in metastatic carcinoma ex pleomorphic adenoma with FGFR2–BICC1 fusion: a case report
This case highlights the prolonged clinical response to pemigatinib in a patient with metastatic carcinoma ex pleomorphic adenoma harboring an FGFR2-BICC1 fusion, emphasizing the potential role of FGFR inhibition in rare salivary gland malignancies with actionable genomic alterations.
Authors
- C. M. Franco (ORCID: https://orcid.org/0000-0001-8823-5522)
- C. Mula
- Diana C. Riera
- Celia Juez Santamaría
Institutions
- Hospital Can Misses (ES)
Publication Details
- Published
- 2025-09-15
- DOI
- https://doi.org/10.22541/au.175793772.22042510/v1
- Primary Topic
- Metastasis and carcinoma case studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00